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Introduction
• Colorectal (CRC) and breast cancer (BC) are two of 
the most diagnosed cancers in the United States. 
They make up an estimated 431,000 new cases 
and an estimated 96,580 deaths, combined1.
• Screening for these cancers is essential to 
diagnosing them early and improving a patient’s 
prognosis. 
• Routine cancer screenings were postponed to limit 
potential spread of the SARS-CoV2 virus2.
• Current research examining the effect of the 
COVID-19 pandemic on CRC and BC screening is 
limited to specific methods or is within a narrow time 
frame.
Methods
• Selecting our cohort:
Results: Breast Cancer Screening
Conclusions
• There was a significant decrease in overall CRC 
screening, each CRC screening modality, and BC 
screening from Q1 2019 through Q2 2020 across the 
United States.
• We also observed a decrease in screening rates by 
approximately 50% during Q2 2020 for BC and CRC.
• When stratifying the data by race, the declining trend 
remained consistent across patient races for overall 
CRC screening, each CRC screening modality, and 
BC screening.
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Objectives
• To analyze how the rates of overall CRC and BC 
screening varied between 2019 through 2020; and, 
to determine how both rates varied across patient 
populations. 
* Eligibility was defined as patients fully insured 
during an entire quarter and eligible for screening 
according to the American Cancer Society: ages 
51 - 75 for CRC and women ages 46 - 74 for BC. 
• We observed a significant declining trend in the overall 
CRC screening rates from 2019 Q1 to 2020 Q2 over six 
quarters (p<0.001). Fig.1 (A)
• We observed a 47% decrease in overall CRC 
screening in Q2 2020 compared to Q4 2019 (p<0.001). 
Fig.1 (A) *
• We also observed a significant declining trend for 
colonoscopy, stool-based CRC screening tests, 
sigmoidoscopy, and CT Colonography over the same 
period. Fig.1 (B-E)
• When stratifying the data by race, the declining trend 
remained consistent and significant across Asian, 
Black, Hispanic, and White patients for overall CRC 
screening. Fig.2
Figure 3. Overall BC screening rate over six quarters (p<0.001)  
Figure 4. BC screening rate by race; A: Asian, B: Black, H: Hispanic, W: White 
Performed the following statistical tests:
• Cochran-Armitage trend test to determine the 
significance of the change in screening rate 
over time.
• Kruskal-Wallis test to compare the screening 
rates of specific quarters.
• We observed a significant declining trend in the 
overall BC screening rates from 2019 Q1 to 2020 
Q2 over six quarters (p<0.001). Fig.3
• We observed a 50% decrease in overall BC 
screening in Q2 2020 compared to Q4 2019 
(p<0.001). Fig.3 *
• When stratifying the data by race, the declining 
trend remained consistent across Asian (A), Black 
(B), Hispanic (H), and White (W) patients for 
overall BC screening (p<0.001). Fig.4
Sourced CRC and BC screening claims data from 
the OPTUM® claims database
Identified 8,656,406 eligible* CRC screening 
and 5,116,717 eligible BC screening patients 
in 2019 through 2020
Determined screening rate per quarter:
No screenings per quarter
No eligible patients per quarter
Figure 1. (A) Overall CRC screening rate over six quarters (p<0.001); (B) 
Colonoscopy rate; (C) Stool-based CRC screening tests rate: fecal 
immunochemical test (FIT), fecal occult blood test (FOBT), and stool DNA test 
(p<0.001 for all); (D) Sigmoidoscopy rate (p=0.0035); (E) CT Colonography rate 
(p=0.0047)
Figure 2. CRC screening rate by race; A: Asian, B: Black, H: Hispanic, W: White 
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